中国肺癌杂志2012，Vol.15Issue(10)：591-596,6.DOI:10.3779/j.issn.1009-3419.2012.10.05
Keap1在非小细胞肺癌中的表达及与化疗疗效相关性的研究
Keap1 Expression for Predicting the Chemoresistance and Prognosis of Advanced Non-small Cell Lung Cancer
摘要
Abstract
Background and objective It has been proven that Kekh-like ECH-associated protein 1 (Keapl) expression was correlated with the chemoresistance of platinum drugs. The aim of this study is to investigate the protein expression levels of Keap 1 in non-small cell lung cancer (NSCLC) patients as well as to correlate its expression with the response rate (RR), progression-free survival (PFS), and overall survival (OS) of patients treated with platinum-based first-line chemotherapy. Methods The immunohistochemical analysis of Keapl expression was performed using tumor samples from SO patients with stage Ⅲ or Ⅳ NSCLC. Results The high expression ratio of Keapl was 26.0%. The Keapl expression was significantly correlated with the RR and PFS after platinum-based chemotherapy (P<0.05) but not with the gender, age, smoking, pathology type, differentiation, metastasis, and OS (P>0.05). The PFS was significantly longer in patients with high Keap 1 expression than in those with low/negative expression (P=0.002). Furthermore, the level of Keap 1 expression was an independent predictive factor of PFS after platinum-based first-line chemotherapy (P=0.007). Conclusion The expression of Keapl was significantly correlated with the RR and PFS of platinum-based first line chemotherapy. Therefore, Keapl may be a useful biomarker for predicting the chemosensitivity of patients with advanced-stage NSCLC.关键词
肺肿瘤/Keap1/化疗/无进展生存期Key words
Lung neoplasms/Kelch-like ECH-associated protein 1/Chemotherapy/Progression free survival分类
医药卫生引用本文复制引用
曹宝山,朱翔,陈森,肖宇,梁莉..Keap1在非小细胞肺癌中的表达及与化疗疗效相关性的研究[J].中国肺癌杂志,2012,15(10):591-596,6.基金项目
本研究受北京大学第三医院中青年骨干基金(No.76476-01)资助 （No.76476-01）
